InvestorsHub Logo
Followers 4
Posts 171
Boards Moderated 0
Alias Born 03/02/2015

Re: None

Tuesday, 07/05/2022 9:18:14 AM

Tuesday, July 05, 2022 9:18:14 AM

Post# of 863
OTLK - Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 5, 2022 ISELIN, N.J., July 05, 2022

(GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”).

All obligations under the Note have been repaid in cash and satisfied.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News